TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06096818

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental Group: Kegel exercises and abdominal exercises
Description: The training was planned to occur 3 times in a 12-week period (first meeting+6thweek+12th week). Each training: approx. 30 min.~First session:Meeting the woman Consent and data collection forms (Descriptive characteristics of women, Incontinence Impact Questionnaire-Short Form,International Urinary Incontinence Consultation Questionnaire-Short Form,Pittsburgh Sleep Quality Scale) Information about stress urinary incontinence is given The woman is given kegel exercise and abdominal exercise training face to face by the researchers.~Kegel and abdominal exercise application chart is explained and given as homework.~Relevant brochure is provided. Second Session:Greeting-Kegel and abdominal exercise application chart is being checked Kegel and abdominal exercises are performed again under the supervision of the researcher.~Third session:Greeting-Kegel and abdominal exercise application chart is being checked Data collection tools are being refilled.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control Group: Kegel exercises
Description: The training was planned to occur 3 times in a 12-week period (first meeting+6th week+12th week). Each training: approx. 20 min.~First session: Meeting the woman Consent and data collection forms (Descriptive characteristics of women, Incontinence Impact Questionnaire-Short Form, International Urinary Incontinence Consultation Questionnaire-Short Form, Pittsburgh Sleep Quality Scale).~Information about stress urinary incontinence is given The woman is given kegel exercise training face to face by the researchers. Kegel exercise application chart is explained and given as homework. Relevant brochure is provided. Second Session:Greeting-Kegel exercise application chart is being checked Kegel exercises are performed again under the supervision of the researcher. Third session:Greeting-Kegel exercise application chart is being checked Data collection tools are being refilled.
Study: NCT06475027

Intervention type: OTHER
Intervention: TBDESJS
Description: Chinese herbal tea TBDESJS

Intervention type: OTHER
Intervention: TBDESJS
Description: Chinese herbal tea TBDESJS

Intervention type: OTHER
Intervention: Acupuncture
Description: acupuncture GB20 or GB20 plus BL2

Intervention type: OTHER
Intervention: Acupuncture
Description: acupuncture GB20 or GB20 plus BL2

Intervention type: OTHER
Intervention: Acupuncture
Description: acupuncture GB20 or GB20 plus BL2

Intervention type: OTHER
Intervention: Acupuncture
Description: acupuncture GB20 or GB20 plus BL2
Study: NCT06304558

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-Invasive Neuromodulation (NESA)
Description: Considering the objectives set: In the first phase, the directing electrode will be located at C6-C7 to generate a systemic and general effect on the organism, with program 1, program 2, program 7, and program 8. In the second phase, the directing electrode will be placed at the abdominal level in the area of the mesenteric plexus to influence the sympathetic innervation of the viscera. In the third phase, the directing electrode is located at S2-S3 to concentrate the action of the therapy on the sacral parasympathetic plexus,. In this way, both the sympathetic and parasympathetic innervation of the main sexual organs are covered through the sympathetic paravertebral ganglia and the sacral plexus.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Non-Invasive Neuromodulation (NESA)
Description: Considering the objectives set: In the first phase, the directing electrode will be located at C6-C7 to generate a systemic and general effect on the organism, with program 1, program 2, program 7, and program 8. In the second phase, the directing electrode will be placed at the abdominal level in the area of the mesenteric plexus to influence the sympathetic innervation of the viscera. In the third phase, the directing electrode is located at S2-S3 to concentrate the action of the therapy on the sacral parasympathetic plexus,. In this way, both the sympathetic and parasympathetic innervation of the main sexual organs are covered through the sympathetic paravertebral ganglia and the sacral plexus.
Study: NCT05347134

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SKB264
Description: SKB264 ：5 mg/kg, IV (in the vein) on day 1 and Day 15 of each 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.~Eribulin:1.4mg/m2, IV (in the vein) on day 1 and Day 8 of each 281day cycle. Number of Cycles: until progression or unacceptable toxicity develops.~Capecitabine:1000-1250mg/m2, po,bid, from day 1 to Day 15 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.~Gemcitabine:800-1000 mg/m2, IV (in the vein) on day 1 and Day 8 of each 281day cycle. Number of Cycles: until progression or unacceptable toxicity develops.~Vinorelbine:25 mg/m2, IV (in the vein) on day 1 and Day 8 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SKB264
Description: SKB264 ：5 mg/kg, IV (in the vein) on day 1 and Day 15 of each 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.~Eribulin:1.4mg/m2, IV (in the vein) on day 1 and Day 8 of each 281day cycle. Number of Cycles: until progression or unacceptable toxicity develops.~Capecitabine:1000-1250mg/m2, po,bid, from day 1 to Day 15 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.~Gemcitabine:800-1000 mg/m2, IV (in the vein) on day 1 and Day 8 of each 281day cycle. Number of Cycles: until progression or unacceptable toxicity develops.~Vinorelbine:25 mg/m2, IV (in the vein) on day 1 and Day 8 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
Study: NCT04722952

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Visilizumab
Description: Azacytidine 75mg/(m2.d) by IV on days 1-7 of every cycle. Anti-PD-1 mAb 200mg by IV on day 8 of every cycle. Homoharringtonine(HHT) 2mg/(m2.d) by IV on days 1-6 of every cycle Cytarabine 10mg/(m2.d) by SC on days 1-7 of every cycle Granulocyte colony-stimulating factor(G-CSF) 300ug/d by SC on days 1-7 of every cycle，until absolute neutrophil count(ANC) \> 5X109／L or white blood cell（WBC）\> 20X109／L.
Study: NCT05191667

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AN0025
Description: 250 mg or 500 mg Q.D., oral administration
Study: NCT05111392

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ingestion of one (1) liter of beverage with observation for 2 h

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Oral Rehydration Solution 1
Description: Ingestion of one (1) liter of beverage with observation for 2 h

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Oral Rehydration Solution 2
Description: Ingestion of one (1) liter of beverage with observation for 2 h
Study: NCT06400407

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Theta-burst Stimulation
Description: Based on the map, an 8-shaped coil was used to stimulate the motor function-related targets. The stimulation intensity was RMT80%, 600 pulses, 50Hz, 40s per target, and the stimulation interval was more than 2 hours. The total course of treatment lasted 7 days.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation
Description: A Sham stimulation coil was used to stimulate based on the map. The sound and duration were the same as the cTBS group, ensuring no effective stimulation. The total course of treatment lasted 7 days.
Study: NCT05482165

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multi-faceted health promotion programme
Description: This intervention programme will target the influencing factors of childhood obesity to influence the knowledge, attitude and behaviours of school children. Students in the intervention group will receive the following interventions:~* Develop and implement school policies related to weight loss~* Distribute health education materials on diet and exercise to students~* Carry out student health education courses
Study: NCT05921149

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fasting Mimicking Diet (Xentigen by L'Nutra)
Description: L-Nutra Xentigen is a product which will provide all the food to be consumed by subjects during 3 days prior to chemotherapy and for 24 hours after chemotherapy. Xentigen is a plant-based diet program designed to attain fasting-like effects while providing both macro- and micronutrients to minimize the burden of fasting and adverse effects. The FMD consists of 100% ingredients that are generally regarded as safe (GRAS) and comprises proprietary vegetable-based soups and broths, energy bars, energy drinks, cracker snacks, herbal teas, and supplements. The FMD consists of a 4-day regimen that provides approximately 1100 kilocalories for the first day and approximately 500 kilocalories per day for the second to the fourth day. Subsequently, a day 5 of transition diet (approximately 800 kilocalories) is provided to avoid the refeeding syndrome.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Given IV

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Standard diet
Description: Normal diet
Study: NCT05101083

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: New Receiver-in-Canal Device
Description: Successor of previous device generation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Legacy Receiver-in-Canal Device
Description: Receiver-in-canal device available on the market
Study: NCT05463926

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PDA mobile application
Description: Parentbot - a Digital healthcare Assistant (PDA):~A mobile application-based psychosocial parenting intervention with integrated chatbot features. It consists of multimedia educational materials (text files, audio files and videos), discussion forums, guided mindfulness-based meditation videos, guided reflection and gratitude journals and a chatbot.
Study: NCT05899621

Intervention type: DRUG
Intervention: Obinutuzumab
Description: Obinutuzumab IV infusion will be administered as per the schedule specified in the respective arm.

Intervention type: DRUG
Intervention: Obinutuzumab
Description: Obinutuzumab IV infusion will be administered as per the schedule specified in the respective arm.

Intervention type: DRUG
Intervention: Obinutuzumab
Description: Obinutuzumab IV infusion will be administered as per the schedule specified in the respective arm.

Intervention type: DRUG
Intervention: Lenalidomide
Description: Lenalidomide PO will be administered as per the schedule specified in the respective arm.

Intervention type: DRUG
Intervention: Bendamustine
Description: Bendamustine IV infusion will be administered as per the schedule specified in the respective arm.

Intervention type: DRUG
Intervention: Cyclophosphamide
Description: Cyclophosphamide IV infusion will be administered as per the schedule specified in the respective arm.

Intervention type: DRUG
Intervention: Doxorubicin
Description: Doxorubicin IV infusion will be administered as per the schedule specified in the respective arm.

Intervention type: DRUG
Intervention: Vincristine
Description: Vincristine IV infusion will be administered as per the schedule specified in the respective arm.

Intervention type: DRUG
Intervention: Prednisone
Description: Prednisone PO will be administered as per the schedule specified in the respective arm.
Study: NCT05098756

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Art therapy
Description: The art therapy in this study is once a week, 90 minutes each section for a total of 8-week, and using theme-oriented group art therapy. Each section has one theme, and the researcher guides the elderly to make artistic creations. Each section includes a warm-up phase is 15 minutes, the creative phase is 60 minutes, and sharing phase is 15 minutes.
Study: NCT05362760

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib + Aromatase Inhibitor
Description: Abemaciclib 150 mg orally every 12 hours plus Aromatase Inhibitor ( Anastrozole 1 mg, Letrozole 2.5 mg or exemestane 25 mg orally every 24 hours on Days 1 to 28 of a 28-day cycle)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib + Fulvestrant
Description: Abemaciclib 150 mg orally every 12 hours plus Fulvestrant (500 mg intramuscularly on Days 1 and 15 of Cycle 1, then on Day 1 of Cycle 2 and beyond on Day 1 of a 28-day cycle)
Study: NCT06041178

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2.5% flurbiprofen
Description: Gel was made of 20% poloxamer and 10% ethanol as an Optimum formulation with sustained release up to 48 hours and a reasonable sol gel transition phase (adjunctive to SRP)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2.5% flurbiprofen
Description: Gel was made of 20% poloxamer and 10% ethanol as an Optimum formulation with sustained release up to 48 hours and a reasonable sol gel transition phase (adjunctive to SRP)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 98% aloe vera
Description: the Aloe vera gel employed possessed a concentration of 98% and was obtained from the reputable brand Avivir (Denmark). The remaining 2% comprised normal saline. The process of obtaining the 98% Aloe vera gel involved meticulous washing of mature Aloe Vera leaves under running water, followed by the removal of their outer skin. Subsequently, each leaf was divided into smaller pieces, from which the gel was allowed to seep out and carefully collected in a sterile container. The collected gel was then stored at 4°C until the time of its application in the study (adjunctive to SRP)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 98% aloe vera
Description: the Aloe vera gel employed possessed a concentration of 98% and was obtained from the reputable brand Avivir (Denmark). The remaining 2% comprised normal saline. The process of obtaining the 98% Aloe vera gel involved meticulous washing of mature Aloe Vera leaves under running water, followed by the removal of their outer skin. Subsequently, each leaf was divided into smaller pieces, from which the gel was allowed to seep out and carefully collected in a sterile container. The collected gel was then stored at 4°C until the time of its application in the study (adjunctive to SRP)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: saline

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: saline
Study: NCT04212897

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music Therapy
Description: Participants in the intervention arm will be asked to practice a rhythmic auditory synchronous finger tapping intervention task at home for a total of 25 minutes split between two ten-minute sets with a five-minute break between the sets every day for 8-weeks. During training sessions participants must listen to the instrumental of a pre-selected well-known Chinese melody, Moonlight over the Lotus Pond by Phoenix Legend, whose melody duration is 259s. This song was selected for its strong beat and familiarity to the participants. Participants must follow the beats of the melody and tap their right index finger simultaneously to the beats. A visual cue will be displayed to indicate the beats, identical to the one in the assessment. The training session will be conducted once daily after patients have taken their medication. Participants' primary caretaker will be asked to monitor and record completion of sessions.
Study: NCT05592769

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HealthBeacon Injection Care Management System (ICMS)
Description: All participants will receive access to the HealthBeacon ICMS to remotely monitor adherence to therapy in the home setting. The system includes the following items/services:~* The HealthBeacon Smart Sharps Bin~* The HealthBeacon Companion App~* HealthBeacon Care Team Support (including smart dose reminders and intervention calls)~* Waste Management Services~Participants will also be issued the following interventions to enable collection of the secondary endpoints:~-Participant Feedback Questionnaire (issued electronically upon study completion, to gather feedback on the HealthBeacon ICMS)
Study: NCT05583708

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 400mg IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lutetium Lu 177 dotatate
Description: 7.4GBq (200 mCi) IV
Study: NCT06434233

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: All patients will receive Acetaminophen 500 mg orally every 6 hours scheduled x 30 tablets at post-operative discharge.~All patients will be instructed to take Acetaminophen around the clock for the first 72 hours and as needed thereafter.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: All patients will receive Acetaminophen 500 mg orally every 6 hours scheduled x 30 tablets at post-operative discharge.~All patients will be instructed to take Acetaminophen around the clock for the first 72 hours and as needed thereafter.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: All patients will receive Ibuprofen 600 mg orally every 6 hours scheduled x 30 tablets at post-operative discharge.~All patients will be instructed to take Ibuprofen around the clock for the first 72 hours and as needed thereafter.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: All patients will receive Ibuprofen 600 mg orally every 6 hours scheduled x 30 tablets at post-operative discharge.~All patients will be instructed to take Ibuprofen around the clock for the first 72 hours and as needed thereafter.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone
Description: Patients randomized to Arm 1 will receive Oxycodone 5 mg orally every 4 hours as needed x 12 tablets at post-operative discharge~Patients randomized to Arm 2 will not receive an Oxycodone prescription at post-operative discharge.~However, participants will be informed that if they need additional pain medications, these will not be withheld. Participants in the second arm who require additional pain medications will receive the same amount of Oxycodone as in arm 1
Study: NCT05958745

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: Aerobic exercise training Program

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic + resistance exercise
Description: Aerobic + resistance exercise training Program
Study: NCT06354790

Intervention type: OTHER
Intervention: Motor evaluations
Description: Evaluation of patients motor function using motor scales (MFM32, RULM), Timed functioned tests (6MWT, Rise from floor, 4SCT, 10mWT), dynamometric strength evaluation (grip, pinch, flexion/extension)

Intervention type: OTHER
Intervention: Cognitive assessment
Description: Patients cognitive evaluation (WPPSI-IV, WISC-V)

Intervention type: OTHER
Intervention: Pulmonary function test
Description: Evaluation of patients' respiratory function (FVC, PCF, MIP, MEP, SNIP)

Intervention type: OTHER
Intervention: Cardiac evaluation
Description: Evaluation of patients' cardiac function (ECG, Echo-cardiography)

Intervention type: OTHER
Intervention: Quality of life
Description: Evaluation of patients quality of life with questionnaires and PROM

Intervention type: OTHER
Intervention: Spine X Ray
Description: Evaluation of spinal deformities by X-ray

Intervention type: OTHER
Intervention: Muscular MRI
Description: Evaluation of a qualitative whole-body muscle part and a quantitative lower limb muscle part by MRI

Intervention type: OTHER
Intervention: Biomarkers collection and analysis
Description: Collection of blood and urinary sample for biomarkers research.
Study: NCT05941741

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Intensity Modulated Radiation Therapy
Description: All target volumes will be outlined slice by slice on the axial contrast-enhanced CT with MR fusion images in the treatment planning system. The target volumes are defined in accordance with the International Commission on Radiation Units and Measurements Reports 83. The prescribed dose is 70-72 Gy to PTVp (Planning target volume of the primary tumor), 64-70 Gy to PTVn (Planning target volume of the lymph node), 60- 64Gy to PTV1 (High-risk planning target volume), and 54-58 Gy to PTV2 (Low-risk planning target volume) in 30-32 fractions.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity Modulated Radiation Therapy
Description: All target volumes will be outlined slice by slice on the axial contrast-enhanced CT with MR fusion images in the treatment planning system. The target volumes are defined in accordance with the International Commission on Radiation Units and Measurements Reports 83. The prescribed dose is 70-72 Gy to PTVp (Planning target volume of the primary tumor), 64-70 Gy to PTVn (Planning target volume of the lymph node), 60- 64Gy to PTV1 (High-risk planning target volume), and 54-58 Gy to PTV2 (Low-risk planning target volume) in 30-32 fractions.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Induction chemotherapy: gemcitabine and cisplatin, Q3W, 3 cycles Concurrent chemotherapy: cisplatin, Q3W, 2-3 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Induction chemotherapy: gemcitabine and cisplatin, Q3W, 3 cycles Concurrent chemotherapy: cisplatin, Q3W, 2-3 cycles

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Immune checkpoint inhibitor
Description: Cadonilimab: 10mg/kg, Q3W, 3 cycles

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Low-dose radiotherapy
Description: Low-dose radiotherapy will be performed to study group, with the use of IMRT.
Study: NCT04594941

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flurpiridaz (18F) Injection
Description: All participants received 2 IV boluses of Flurpiridaz (18F) Injection in a large peripheral vein at rest.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flurpiridaz (18F) Injection
Description: All participants received 2 IV boluses of Flurpiridaz (18F) Injection in a large peripheral vein at rest.
Study: NCT06477237

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HB0017 Q4W
Description: HB0017 at W0,1,2,4,8+HB0017Q4W

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HB0017 Q8W
Description: HB0017 at W0,1,2,4,8+HB0017Q8W

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo at W0,1,2,4,8+HB0017Q4W
Study: NCT05571176

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: S-ketamine
Description: S-ketamine infusion 0.29 mg/kg/h for 4 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-ketamine
Description: S-ketamine infusion 0.29 mg/kg/h for 4 hours
Study: NCT06465134

Intervention type: OTHER
Intervention: No intervention
Description: There is no intervention